Table 2.

The accumulative OS, PFS, and local and intrahepatic control of different treatment groups.

		Before propensity matching					After propensity matching
	Months	SBRT	TACE	HR	95% CI	P	SBRT	TACE	HR	95% CI	P
OS	12	86.0%	77.3%	1.79	1.05–3.03	0.031	85.7%	83.6%	1.19	0.57–2.49	0.65
	36	64.7%	51.0%	1.71	1.17–2.51	0.005	65.1%	61.0%	1.17	0.7–1.96	0.55
	60	57.3%	43.8%	1.69	1.17–2.46	0.0046	62.8%	50.4%	1.19	0.79–2.14	0.3
PFS	12	65.9%	47.5%	1.82	1.30–2.57	0.0003	63.4%	53.3%	1.46	0.93–2.28	0.092
	36	38.1%	27.6%	1.62	1.22–2.16	0.0005	35.9%	27.4%	1.37	0.95–1.97	0.081
	60	26.7%	12.4%	1.71	1.30–2.25	0.0001	27.5%	14.2%	1.44	1.01–2.04	0.037
LC	12	85.1%	67.2%	1.79	1.05–3.03	0.0031	86.8%	69.3%	1.93	1.18–3.18	0.0035
	36	63.1%	50.2%	1.93	1.29–2.88	0.0008	62.5%	53.5%	1.81	1.08–3.04	0.0219
	60	59.3%	35.6%	2.04	1.38–3.01	0.0002	56.9%	36.6%	1.93	1.18–3.18	0.0084
IC	12	77.8%	49.6%	2.94	1.99–4.32	0.0001	77.3%	57.3%	2.33	1.39–3.93	0.0016
	36	49.6%	33.5%	2.14	1.54–2.96	0.0001	45.9%	34.1%	1.7	1.12–2.58	0.01
	60	42.9%	15.1%	2.32	1.69–3.17	0.0001	42.4%	17.7%	1.85	1.23–2.77	0.0021